Unlocking the Groundbreaking Potential of iNKT Cells for Allogeneic Cancer Therapy
Time: 2:00 pm
day: Day Two
- Arovella is developing its novel iNKT cell therapy platform to develop allogenic cell therapies to treat cancer.
- Arovella is initially targeting haematological malignancies with its lead product ALA-101. Through a strategic collaboration with Imugene, Arovella will use ALA-101 to target solid tumours.
- Arovella is also developing its DKK1- CARiNKT cells to target multiple myeloma and solid tumours.